{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:03:59Z","timestamp":1769313839615,"version":"3.49.0"},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.2169\/internalmedicine.7581-21","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T22:12:01Z","timestamp":1636755121000},"page":"1731-1734","source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy"],"prefix":"10.2169","volume":"61","author":[{"given":"Daisuke","family":"Tamanoi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Saruwatari","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Jodai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikiko","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Disease, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yonemura","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Ichiyasu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Sakagami","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab. Cancer Treat Rev 62: 39-49, 2018.","DOI":"10.1016\/j.ctrv.2017.10.002"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N England J Med 378: 158-168, 2018.","DOI":"10.1056\/NEJMra1703481"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol 32: 2913-2919, 2014.","DOI":"10.1200\/JCO.2014.55.1143"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 18: 313-322, 2018.","DOI":"10.1038\/nrc.2018.6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sui JD, Wang Y, Wan Y, Wu YZ. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. Drug Des Devel Ther 12: 1645-1657, 2018.","DOI":"10.2147\/DDDT.S167077"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6: e48-e57, 2019.","DOI":"10.1016\/S2352-3026(18)30175-3"},{"key":"7","unstructured":"7. Brahmer JR, Lacchetti C, Schneider BJ, et al.; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kanameishi S, Otsuka A, Nonomura Y, Fujisawa A, Endo Y, Kabashima K. Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol 27: 546-547, 2016.","DOI":"10.1093\/annonc\/mdv580"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 13: 516-524, 2016.","DOI":"10.1038\/nrclinonc.2016.30"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nie M, Liu Y, Li XX, et al. PD-1\/PD-L pathway potentially involved in ITP immunopathogenesis. Thromb Haemost 119: 758-765, 2019.","DOI":"10.1055\/s-0039-1679909"},{"key":"11","doi-asserted-by":"crossref","first-page":"1722023","DOI":"10.1080\/2162402X.2020.1722023","volume":"9","author":"KH Kim","year":"2020","unstructured":"11. Kim KH, Hur JY, Cho J, et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 9: 1722023, 2020.","journal-title":"OncoImmunology","ISSN":"https:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_7581-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T03:31:20Z","timestamp":1654313480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_7581-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7581-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"7581-21"}}